BIO Praises the Release of the 21st Century Cures Initiative Discussion Draft
The Biotechnology Industry Organization (BIO) has released the following statement on the 21st Century Cures Initiative discussion draft shared by Chairman Fred Upton (R-MI).
Jim Greenwood, BIO President and CEO said: “Today, we recognise and thank the Committee on Energy and Commerce for releasing its 21st Century Cures Initiative discussion draft intended to accelerate the discovery, development and delivery of next-generation modern medicines to transform patient care.
“Working with member companies, patient advocacy groups, and other stakeholders, we developed numerous proposals to create a public policy environment that encourages the use of 21st century scientific tools, advancements in molecular biology, and novel bioinformatics to continuously develop and improve upon therapies that can prevent, diagnose and treat all stages of disease.
“We are pleased to see several of our priority suggestions in the discussion draft, including the need for a large-scale national research commitment to study precursors and signs of disease and disease risk factors for chronic conditions. Through the 21st Century Cures Initiative, we hope to work with the Congress, the NIH, and the patient community to develop a study that has the potential to revolutionize our understanding of disease, thus resulting in better treatments and cures.
“We also embrace the focus on precision medicine through genomics and regulatory science. Industrial-scale biomarker qualification and full genome sequencing will help us better understand the molecular basis of disease and develop precision therapies tailored to each patient.
“We believe that placing patients at the center of the drug development process will spur the development of therapies for the most prevalent conditions, as well as encourage development of treatments focused on unmet medical needs. We strongly support establishing a framework for incorporating patient views into the development and regulatory review process in a more structured and transparent way, with respect to benefit-risk assessments and use of patient experience data.
“Further, we support modernising clinical trials to expedite and accelerate drug development through the use of alternative clinical trial designs, biomarkers and surrogate endpoints, and modern scientific approaches and greater utilization of post-market validation and other confirmatory techniques, including the use of real-world data.
“We also strongly support provisions intended to further incentivize biomedical innovation and help expedite the development of new treatments and cures, particularly in areas of unmet medical need where existing incentives may be inadequate to drive sufficient investment.
“In addition, we support enhancing the FDA’s scientific capacity by improving access to adequate funding, recruiting world-class scientific and technical experts, and expanding management processes and human resource functions to meet the complexities of 21st Century scientific discovery.
“While we are still reviewing the many proposals contained within the discussion draft, we look forward to working with Chairman Upton and Rep. DeGette to ensure that the 21st Century Cures Initiative expedites the delivery of the next generation of modern medicines that will save lives and reduce and eliminate suffering.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance